GlassScriptPhysician profile
Sharon Jung
NPI 1699770628
$22,867.09
in general payments reported to CMS, 2019-2025
27 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,368 · 2022: $4,299 · 2023: $5,261 · 2024: $2,747 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,417 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Education: $1,360 · Consulting Fee: $795 · Travel and Lodging: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,416.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Education | $1,360.32 |
| Consulting Fee | $795.00 |
| Travel and Lodging | $628.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $8,858.32 | 2021-2023 | Ongentys, Ingrezza |
| Acorda Therapeutics, INC | $2,467.22 | 2021-2024 | Inbrija |
| Abbvie INC. | $1,781.23 | 2021-2025 | |
| Mdd US Operations, LLC | $1,677.93 | 2021-2023 | Gocovri |
| Boston Scientific Corporation | $1,550.89 | 2021-2023 | Vercise |
| Amneal Pharmaceuticals LLC | $1,521.54 | 2024 | Ongentys 50mg Capsules 30, Ongentys, Rytary |
| Abbott Laboratories | $1,358.98 | 2022 | |
| Lundbeck LLC | $891.53 | 2021-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $435.52 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Acadia Pharmaceuticals INC | $408.10 | 2021-2023 | Nuplazid |
| Merz Pharmaceuticals, LLC | $360.13 | 2021-2024 | Xeomin |
| Pfizer INC. | $327.50 | 2023-2025 | |
| Lilly USA, LLC | $324.09 | 2022-2025 | Emgality, Kisunla, Reyvow |
| Upsher-Smith Laboratories LLC | $167.99 | 2022-2023 | |
| Amgen INC. | $139.39 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $95.41 | 2023-2025 | Nourianz |
| Ipsen Biopharmaceuticals, INC | $94.31 | 2022-2025 | Dysport |
| Biohaven Pharmaceutical Holding Company LTD. | $72.82 | 2022 | |
| Supernus Pharmaceuticals, INC. | $61.42 | 2021-2022 | |
| Revance Therapeutics, INC. | $44.26 | 2024 | Daxxify |
| Ucb, INC. | $43.15 | 2025 | Rystiggo |
| Biohaven Pharmaceuticals, INC. | $40.27 | 2021 | |
| Allergan, INC. | $38.23 | 2021 | |
| Cala Health, INC. | $37.83 | 2024 | Cala Trio, Cala Kiq |
| Impel Pharmaceuticals INC. | $30.74 | 2023 | Trudhesa |
| Arbor Pharmaceuticals, INC. | $20.33 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.96 | 2023 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Jung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.